基蛋生物
(603387)
| 流通市值：42.50亿 | | | 总市值：42.50亿 |
| 流通股本：5.07亿 | | | 总股本：5.07亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 879,824,587.76 | 617,667,779.49 | 321,582,715.19 | 1,369,162,256.52 |
| 营业收入 | 879,824,587.76 | 617,667,779.49 | 321,582,715.19 | 1,369,162,256.52 |
| 二、营业总成本 | 676,679,065.46 | 466,817,209.47 | 220,695,492.33 | 1,081,780,774.83 |
| 营业成本 | 268,955,795.91 | 189,887,885.17 | 91,732,752.11 | 446,065,031.21 |
| 税金及附加 | 10,369,616.26 | 7,560,122.86 | 3,619,422.23 | 13,820,286.75 |
| 销售费用 | 211,870,182.7 | 145,456,121.66 | 66,563,839.18 | 347,441,269.81 |
| 管理费用 | 66,311,847.95 | 47,350,933.99 | 22,276,307.44 | 106,827,694.63 |
| 研发费用 | 137,226,238.04 | 92,414,490.91 | 44,003,300.95 | 217,991,933.84 |
| 财务费用 | -18,054,615.4 | -15,852,345.12 | -7,500,129.58 | -50,365,441.41 |
| 其中:利息费用 | 12,103,543.02 | 7,912,186.19 | 2,912,801.58 | 16,943,082.57 |
| 其中:利息收入 | 32,797,829.28 | 21,486,110.61 | 10,009,461.55 | 56,538,917.73 |
| 加:公允价值变动收益 | 6,504,688.08 | 5,022,669.76 | 1,342,865.38 | 10,245,185.85 |
| 加:投资收益 | 4,670,954.43 | 750,663.64 | -1,280,712.79 | 15,484,562.84 |
| 资产处置收益 | -1,345,758.71 | -1,442,230.82 | 405,149.47 | 668,291.52 |
| 资产减值损失(新) | -3,019,651.26 | -883,998.09 | -818,116.58 | -19,245,951.64 |
| 信用减值损失(新) | -8,058,813.26 | -9,535,842.26 | -6,982,436.01 | -19,211,818.6 |
| 其他收益 | 28,878,683.63 | 21,898,266.54 | 6,877,977 | 31,266,298.99 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 230,775,625.21 | 166,660,098.79 | 100,431,949.33 | 306,588,050.65 |
| 加:营业外收入 | 1,726,499.58 | 1,083,300.48 | 84,900.76 | 1,583,782.5 |
| 减:营业外支出 | 3,160,937 | 1,560,784.56 | 462,308.54 | 3,230,212.98 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 229,341,187.79 | 166,182,614.71 | 100,054,541.55 | 304,941,620.17 |
| 减:所得税费用 | 20,621,255.3 | 15,267,118.53 | 12,617,665.61 | 20,861,171.14 |
| 六、净利润 | 208,719,932.5 | 150,915,496.18 | 87,436,875.95 | 284,080,449.03 |
| 持续经营净利润 | 208,719,932.5 | 150,915,496.18 | 87,436,875.95 | 284,080,449.03 |
| 归属于母公司股东的净利润 | 202,284,549.59 | 146,808,888.87 | 86,013,453.6 | 279,771,914.08 |
| 少数股东损益 | 6,435,382.91 | 4,106,607.31 | 1,423,422.35 | 4,308,534.95 |
| (一)基本每股收益 | 0.4 | 0.29 | 0.17 | 0.55 |
| (二)稀释每股收益 | 0.4 | 0.29 | 0.17 | 0.55 |
| 八、其他综合收益 | 7,716,154.45 | 135,059.72 | 14,913.87 | 362,505.6 |
| 归属于母公司股东的其他综合收益 | 5,748,948.97 | 135,059.72 | 14,913.87 | 362,505.6 |
| 九、综合收益总额 | 216,436,086.95 | 151,050,555.9 | 87,451,789.82 | 284,442,954.63 |
| 归属于母公司股东的综合收益总额 | 208,033,498.56 | 146,943,948.59 | 86,028,367.47 | 280,134,419.68 |
| 归属于少数股东的综合收益总额 | 8,402,588.39 | 4,106,607.31 | 1,423,422.35 | 4,308,534.95 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 带强调事项段的无保留意见 |